AU2015379251A1 - Crystalline forms of efinaconazole - Google Patents

Crystalline forms of efinaconazole Download PDF

Info

Publication number
AU2015379251A1
AU2015379251A1 AU2015379251A AU2015379251A AU2015379251A1 AU 2015379251 A1 AU2015379251 A1 AU 2015379251A1 AU 2015379251 A AU2015379251 A AU 2015379251A AU 2015379251 A AU2015379251 A AU 2015379251A AU 2015379251 A1 AU2015379251 A1 AU 2015379251A1
Authority
AU
Australia
Prior art keywords
efinaconazole
crystalline
theta
degrees
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015379251A
Other languages
English (en)
Inventor
Itai Adin
Hila ELAZARI-SHALOM
Ori RORILK
Yana Sery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wavelength Enterprises Ltd
Original Assignee
Perrigo API Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perrigo API Ltd filed Critical Perrigo API Ltd
Publication of AU2015379251A1 publication Critical patent/AU2015379251A1/en
Assigned to WAVELENGTH ENTERPRISES LTD reassignment WAVELENGTH ENTERPRISES LTD Amend patent request/document other than specification (104) Assignors: PERRIGO API LTD
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2015379251A 2015-01-20 2015-12-02 Crystalline forms of efinaconazole Abandoned AU2015379251A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105390P 2015-01-20 2015-01-20
US62/105,390 2015-01-20
PCT/IL2015/051171 WO2016116919A1 (en) 2015-01-20 2015-12-02 Crystalline forms of efinaconazole

Publications (1)

Publication Number Publication Date
AU2015379251A1 true AU2015379251A1 (en) 2017-07-27

Family

ID=56416514

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015379251A Abandoned AU2015379251A1 (en) 2015-01-20 2015-12-02 Crystalline forms of efinaconazole

Country Status (8)

Country Link
US (1) US20180002310A1 (https=)
EP (1) EP3247399A4 (https=)
JP (1) JP2018502165A (https=)
CN (1) CN107427585A (https=)
AU (1) AU2015379251A1 (https=)
CA (1) CA2974180A1 (https=)
IL (1) IL253479A0 (https=)
WO (1) WO2016116919A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995434A (zh) * 2016-01-25 2017-08-01 广东东阳光药业有限公司 一种三唑类抗真菌药的晶型及其制备方法
KR102597119B1 (ko) 2017-05-19 2023-11-01 가껭세이야꾸가부시기가이샤 에피나코나졸의 제조 및 정제 방법
US20210363129A1 (en) * 2018-12-29 2021-11-25 Viwit Pharmaceutical Co., Ltd. Preparation method for efinaconazole
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0698606T3 (da) * 1993-05-10 1998-08-24 Kaken Pharma Co Ltd Azolylaminderivat
JP3437695B2 (ja) * 1993-05-10 2003-08-18 科研製薬株式会社 アゾリルアミン誘導体
WO2001007643A1 (en) * 1999-07-28 2001-02-01 Kaken Pharmaceutical Co., Ltd. Method for detecting pathogenic microorganism and antimicrobial agent, method for evaluating the drug effect of antimicrobial agent, and antimicrobial agents
US8889155B2 (en) * 2006-12-28 2014-11-18 Kaken Pharmaceutical Co., Ltd. Gel composition for treating mycosis
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US20090175810A1 (en) * 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
FR2938066B1 (fr) * 2008-11-06 2010-12-17 Centre Nat Rech Scient Systeme et procede d'analyse quantitative de la composition elementaire de la matiere par spectroscopie du plasma induit par laser (libs)
CN103080100B (zh) * 2010-08-31 2016-04-27 科研制药株式会社 1-三唑-2-丁醇衍生物的制造方法
CN104292214B (zh) * 2014-09-24 2017-04-05 南京华威医药科技开发有限公司 艾氟康唑及其中间体的合成方法
CN104327047B (zh) * 2014-10-17 2016-04-06 苏州明锐医药科技有限公司 艾菲康唑的制备方法
WO2016181306A1 (en) * 2015-05-12 2016-11-17 Lupin Limited Process for the preparation of efinaconazole
WO2016193917A1 (en) * 2015-06-04 2016-12-08 Glenmark Pharmaceuticals Limited Process for the preparation of efinaconazole

Also Published As

Publication number Publication date
US20180002310A1 (en) 2018-01-04
EP3247399A1 (en) 2017-11-29
CN107427585A (zh) 2017-12-01
IL253479A0 (en) 2017-09-28
JP2018502165A (ja) 2018-01-25
CA2974180A1 (en) 2016-07-28
WO2016116919A1 (en) 2016-07-28
EP3247399A4 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
TWI589575B (zh) 苯并咪唑衍生物之新穎結晶型及其製備方法
WO2017172784A1 (en) Novel salts and crystals
US20080085903A1 (en) Novel crystalline forms of aripiprazole
CA3058209A1 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
WO2016025720A1 (en) Solid state forms of ibrutinib
AU2015296289A1 (en) Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
WO2008017669A1 (en) Purification process of montelukast and its amine salts
JP5899214B2 (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
AU2015379251A1 (en) Crystalline forms of efinaconazole
US7456181B2 (en) Aripiprazole crystalline forms
CZ2007455A3 (cs) Zpusob izolace a cištení montelukastu
JP2013509358A (ja) ビマトプロストの結晶およびその製造方法と用途
TW202033508A (zh) 貝前列素-314d晶體及其製備方法
CN105753733A (zh) Ahu377的晶型及其制备方法与用途
WO2014173377A2 (en) New crystalline forms of apixaban and a method of their preparation
EP2825525A1 (en) New polymorphic form of a long-acting beta-2 adrenoceptor agonist
EP2771312B1 (en) Agomelatine-urea complex and crystalline forms thereof
WO2011029005A1 (en) Crystalline forms of fesoterodine fumarate and fesoterodine base
EP2085397A1 (en) Crystalline form of abacavir
WO2012125993A1 (en) Solid state forms of rilpivirine base, and rilipivirine salts
KR101525296B1 (ko) 라미부딘 옥살레이트 및 이의 제조방법
TW201536759A (zh) 製備嘧啶中間物之方法
TW202402753A (zh) 高純度化合物之製造方法及純化方法
WO2011039670A1 (en) Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)
TW201815779A (zh) （ｒ）－５－（３，４－二氟苯基）－５－〔（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基〕咪唑啶－２，４－二酮之製造方法及用於該製造之中間體

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: WAVELENGTH ENTERPRISES LTD

Free format text: FORMER NAME(S): PERRIGO API LTD

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period